Spectrum Pharmaceuticals to Begin Phase I Trial of SPI-1620

Spectrum Pharmaceuticals announced that the FDA has cleared the investigational new drug application for the use of SPI-1620 in patients with recurrent or progressive carcinoma.

According to Spectrum, SPI-1620 is being developed as an adjunct to chemotherapy.

The Phase I trial is an open label, dose-escalation study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with recurrent or progressive carcinoma, the company said.

The company added that it expects the trial to begin enrolling patients once the investigational review boards approve the study.